Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

Stéphane Prost (), Francis Relouzat, Marc Spentchian, Yasmine Ouzegdouh, Joseph Saliba, Gérald Massonnet, Jean-Paul Beressi, Els Verhoeyen, Victoria Raggueneau, Benjamin Maneglier, Sylvie Castaigne, Christine Chomienne, Stany Chrétien, Philippe Rousselot and Philippe Leboulch ()
Additional contact information
Stéphane Prost: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
Francis Relouzat: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
Marc Spentchian: Hôpital Mignot
Yasmine Ouzegdouh: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
Joseph Saliba: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
Gérald Massonnet: Unité de Biologie Cellulaire, UMR-S-940 Institut Universitaire d'Hématologie, Hôpital Saint Louis
Jean-Paul Beressi: Service d’Endocrinologie et de Diabétologie, Hôpital Mignot
Els Verhoeyen: CIRI, International Center for Infectiology Research, EVIR team, Inserm, U1111, CNRS, UMR5308, Université de Lyon-1, ENS de Lyon
Victoria Raggueneau: Laboratoire d’hématologie, Centre Hospitalier de Versailles
Benjamin Maneglier: Unité de Pharmacologie, Service de Biologie Médicale, Centre Hospitalier de Versailles
Sylvie Castaigne: Service d’Hématologie et d’Oncologie, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines
Christine Chomienne: Unité de Biologie Cellulaire, UMR-S-940 Institut Universitaire d'Hématologie, Hôpital Saint Louis
Stany Chrétien: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
Philippe Rousselot: Unité de Biologie Cellulaire, UMR-S-940 Institut Universitaire d'Hématologie, Hôpital Saint Louis
Philippe Leboulch: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)

Nature, 2015, vol. 525, issue 7569, 380-383

Abstract: Although imatinib gives good clinical results in chronic myeloid leukaemia (CML), residual disease attributed to quiescent CML stem cells remains in many patients; here glitazones are shown to reduce the pool of CML stem cells and achieve lasting disease eradication in CML patients in combination with imatinib.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature15248 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:525:y:2015:i:7569:d:10.1038_nature15248

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature15248

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().